ABCSG 30/BETH Summary
Multicenter, phase III, randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab.
|Coordinating investigator:||Steger, Günther; Vienna|
(Click to enlarge)
Link for studyteam-members only
Further information about this trial
Access to these informations only with keyword. If required, please ask the responsible project manager.